Skip to main content
Article thumbnail
Location of Repository

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: Marker candidates for dementia with Lewy bodies

By Brit Mollenhauer, Petra Steinacker, Erik Bahn, Mirko Bibl, Peter Brechlin, Michael G. Schlossmacher, Joseph J. Locascio, Jens Wiltfang, Hans A. Kretzschmar, Sigrid Poser, Claudia Trenkwalder and Markus Otto

Abstract

Background: The measurement of biomarkers in cerebrospinal fluid (CSF) has gained increasing acceptance in establishing the diagnosis of some neurodegenerative diseases. Heart-type fatty acid-binding protein (H-FABP) was recently discovered in CSF and serum of patients with neurodegenerative diseases. Objective: We investigated H-FABP in CSF and serum alone and in combination with CSF tau protein to evaluate these as potential biomarkers for the differentiation between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Methods: We established H-FABP and tau protein values in a set of 144 persons with DLB (n = 33), Parkinson disease with dementia (PDD; n = 25), AD (n = 35) and nonclemented neurological controls (NNC; n = 51). Additionally, serum H-FABP levels were analyzed in idiopathic Parkinson disease patients without evidence of cognitive decline (n = 45) using commercially available enzyme-linked immunosorbent assays. We calculated absolute values of HFABP and tau protein in CSF and serum and established relative ratios between the two to obtain the best possible match for the clinical working diagnosis. Results: Serum HFABP levels were elevated in DLB and PDD patients compared with NNC and AD subjects. To better discriminate between DLB and AD, we calculated the ratio of serum H-FABP to CSF tau protein levels. At the arbitrary chosen cutoff ratio >= 8 this quotient reached a sensitivity of 91% and a specificity of 66%. Conclusion: Our results suggest that the measurement of CSF tau protein, together with H-FABP quantification in serum and CSF, and the ratio of serum H-FABP to CSF tau protein represent marker candidates for the differentiation between AD and DLB. Copyright (c) 2007 S. Karger AG, Basel.

Topics: Medizin, ddc:610
Publisher: Ludwig-Maximilians-Universität München
Year: 2007
DOI identifier: 10.1159/000105157
OAI identifier: oai:epub.ub.uni-muenchen.de:16589
Provided by: Open Access LMU

Suggested articles

Citations

  1. (2003). 1 G u i l l a u m e E , Z i m m e r m a n n C , B u r k h a r d PR, Hochstrasser DF, Sanchez JC: A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics
  2. (2007). A platform for the quantification of alpha-synuclein in cerebrospinal fluid: Evidence for a potential biomarker for synucleinopathies. Neurodegenerative Dis
  3. (2003). al: Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol
  4. (2005). al: Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.
  5. (2006). al: Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.
  6. (2001). al: Practice parameter: diagnosis of dementia (an evidence-based review).
  7. (2004). al: Rivastigmine for dementia associated with Parkinson’s disease.
  8. (2006). al: Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1–42), and beta-amyloid(1–40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med
  9. (1997). Alphasynuclein in Lewy bodies. Nature
  10. (2001). AW: Fatty acidbinding proteins of nervous tissue.
  11. (1978). Basic principles of ROC analysis.
  12. (2004). Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem
  13. (2003). Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord
  14. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia.
  15. Consortium on DLB: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology
  16. (2003). Decreased -amyloid and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
  17. (2003). Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells.
  18. (2003). Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol
  19. (1999). E, et al: Sensitivity, specificity, and stability of CSFtau in AD in a community-based patient sample. Neurology
  20. (2005). EJ: Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice.
  21. (1984). EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force Alzheimer’s disease. Neurology
  22. (2005). et al: Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast.
  23. et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
  24. (2005). et al: Tau protein, beta-amyloid (1–42) and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord
  25. (2004). Feany MB: Yeast genetics targets lipids in Parkinson’s disease. Trends Genet
  26. (2005). Glatz JF: Detection of brain injury by fatty acid-binding proteins. Clin Chem Lab Med
  27. (2004). Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett
  28. (1998). Hermens WT: Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta
  29. (1999). Ivanoiu A, et al: Improved discrimination of AD-patients using -amyloid(1–42) and tau levels in CSF. Neurology
  30. (2005). JF: Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta
  31. (1997). JF: One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein. Ann Clin Biochem
  32. l o c h - R o h r J , A l l a r d L , H o c h s t r a s s e r D F , Sanchez JC: Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics
  33. (1992). Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.
  34. (2003). Leitlinien für Diagnostik und Therapie in der Neurologie.
  35. (2004). Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int
  36. (2004). Lewy body-related alpha-synucleinopathy in the aged human brain.
  37. (1987). members of the UPDRS Development Committee: Unified Parkinson’s Disease Rating Scale;
  38. (2006). Monitoring of -synuclein steady -state levels in vivo by ELISA. Mov Disord
  39. (2003). National Institute on Aging Biological Markers Working Group: Biological markers for therapeutic trials in Alzheimer’s disease.
  40. (2004). Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s disease. Acta Neuropathol
  41. (2005). Pelsers MM: Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke.
  42. (2001). Selkoe DJ: Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins.
  43. (2003). Selkoe DJ: Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies.
  44. (2003). Selkoe DJ: The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron
  45. (2003). Steur ENH, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging
  46. (2003). Treatment of advanced Parkinson’s disease: an evidence-based analysis. Adv Neurol
  47. Vusse GJ: Release of fatty acidbinding protein into plasma after acute myocardial infarction in man.
  48. (1967). Yahr MD: Parkinsonism: onset and mortality. Neurology

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.